StockMarketWire.com - Circassia Pharmaceuticals, a speciality pharmaceutical company focused on respiratory disease, has announced the European launch of the NIOX VERO nasal application for the screening of primary ciliary dyskinesia (PCD).

Circassia launched the application at the world's largest meeting of respiratory professionals, the European Respiratory Society (ERS) 2017 International Congress in Milan, Italy.


At 8:01am: [LON:CIR] Circassia Pharmaceuticals Plc share price was -1p at 87.5p



Story provided by StockMarketWire.com